The major problem in therapy of acute myeloid leukemia (AML), like most cancers, is therapeutic resistance. Although >85% of patients respond to chemotherapy, over half will relapse. Chemotherapeutic resistance implies heterogeneity among cancer cells. Two hypotheses exist to explain this heterogeneity. The stem cell hypothesis proposes a functional heterogeneity within an ordered structure in which the bulk of leukemic cells differentiate from leukemic stem cells (LSC). In this model, LSCs are intrinsically resistant to chemotherapy. Consequently, relapsed tumors arise from LSCs and their genetic diversity will reflect that of the original tumor. As such, chemotherapeutics are targeted toward the genetic lesion found within the LSC. The clonal evolution model proposes that there is heritable variation between cells, some or all of which have the potential to form a new tumor. External stressors, such as chemotherapeutics, apply evolutionary stress on the entire population, driving clonal evolution and selecting for resistant clones. In this model, (epi)genetic diversity in the original tumor will increase the probability of chemoresistance, due to the wider repertoire of mutations that could provide a selective advantage. Moreover, as tumor cells evolve and develop new mechanisms of resistance, the profile of genetic and epigenetic lesions in the relapsed tumor continues to change. Accordingly, optimal therapy will require a mix of therapeutics with diverse mechanistic bases. Here, we will test our hypothesis that chemotherapy resistance in AML is best modeled by clonal evolution and utilize our results to better understand the mechanism(s) of chemotherapy resistance in AML.
In Specific Aim 1, we will use a novel xenotransplantation model of AML to determine empiricially if LSCs are enriched after chemotherapy.
In Specific Aim 2, we will use innovative single cell approaches to characterize a cohort of 30 AML paired samples (de novo diagnosis vs. relapse) for clonal diversity to determine if therapy selects for clones.
In Specific Aim 3, we will perform an exploratory study to determine if clonal diversity (as measured by a novel emulsion bisulfite sequencing (BBS) assay) predicts the probability of relapse in AML patients.
Specific Aim 4 will identify and confirm gene mutations that are selected by chemotherapy, by performing RNA sequencing and SNP arrays to compare the level of expression, sequence of expressed genes and copy number alterations between the de novo and relapsed AML from 30 matched pairs of patient samples. Through these diverse approaches, we will test the several features of the LSC vs. clonal evolution models of chemotherapy resistance. These results will have important implications for the development of novel therapeutics for AML, the treatment of chemoresistant disease and the prevention of relapse.

Public Health Relevance

Acute myeloid leukemia (AML) is a malignant disease of the blood which affects almost thirteen thousand Americans each year and leads to death of approximately 10,000 people per year. The disease is refractory to chemotherapy but the mechanism of chemotherapy resistance is not understood. In this application, we will study the mechanism of chemotherapy resistance in AML in order to develop better therapy for AML.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA149566-04
Application #
8606198
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Mufson, R Allan
Project Start
2011-02-10
Project End
2016-01-31
Budget Start
2014-05-09
Budget End
2015-01-31
Support Year
4
Fiscal Year
2014
Total Cost
$575,611
Indirect Cost
$76,870
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Andor, Noemi; Maley, Carlo C; Ji, Hanlee P (2017) Genomic Instability in Cancer: Teetering on the Limit of Tolerance. Cancer Res 77:2179-2185
Lote, H; Spiteri, I; Ermini, L et al. (2017) Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. Ann Oncol 28:1243-1249
Fortunato, Angelo; Boddy, Amy; Mallo, Diego et al. (2017) Natural Selection in Cancer Biology: From Molecular Snowflakes to Trait Hallmarks. Cold Spring Harb Perspect Med 7:
Farge, Thomas; Saland, Estelle; de Toni, Fabienne et al. (2017) Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. Cancer Discov 7:716-735
Tollis, Marc; Boddy, Amy M; Maley, Carlo C (2017) Peto's Paradox: how has evolution solved the problem of cancer prevention? BMC Biol 15:60
Smith, Catherine C; Paguirigan, Amy; Jeschke, Grace R et al. (2017) Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood 130:48-58
Martinez, Pierre; Timmer, Margriet R; Lau, Chiu T et al. (2016) Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus. Nat Commun 7:12158
Luskin, Marlise R; Gimotty, Phyllis A; Smith, Catherine et al. (2016) A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. JCI Insight 1:
Timmer, Margriet R; Martinez, Pierre; Lau, Chiu T et al. (2016) Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study. Gut 65:1602-10
Chowell, Diego; Boddy, Amy M; Mallo, Diego et al. (2016) When (distant) relatives stay too long: implications for cancer medicine. Genome Biol 17:34

Showing the most recent 10 out of 42 publications